Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q15007

UPID:
FL2D_HUMAN

ALTERNATIVE NAMES:
Female-lethal(2)D homolog; WT1-associated protein; Wilms tumor 1-associating protein

ALTERNATIVE UPACC:
Q15007; Q5TCL8; Q5TCL9; Q96T28; Q9BYJ7; Q9H4E2

BACKGROUND:
The Pre-mRNA-splicing regulator WTAP, known for its alternative names such as Female-lethal(2)D homolog, WT1-associated protein, and Wilms tumor 1-associating protein, is integral to RNA modifications. It is involved in the m6A methylation of RNAs via the WMM complex, a process vital for mRNA splicing and RNA processing. WTAP's role extends to regulating mRNA splicing, enhancing the stability of CCNA2 mRNA to regulate the G2/M cell-cycle transition, and impairing WT1 DNA-binding ability, thereby inhibiting WT1 target gene expression.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Pre-mRNA-splicing regulator WTAP could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.